GSK plc (GSK) Stock
GSK has an Alpha Score of 44 out of 100 (weak), computed on Oct 31, 2026 from 3 of 4 sub-scores. 16 members of Congress disclosed 53 trades in GSK since 2015: 35 purchases and 18 sales, most recently Lisa McClain (sale, Oct 31, 2025). 6 of the hedge funds AlphaScala tracks reported GSK in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $139.06M. Its trailing P/E ratio is 16.7 and its net margin 13.0% (key statistics as of Oct 31, 2026).
What is GSK's Alpha Score?
How it works →Alpha Score of 44 reflects weak overall profile with weak momentum, moderate value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 31, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded GSK plc (GSK)?
Most recent: Lisa McClain (sale, Oct 31, 2025); records start May 27, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Val Hoyle D-OR · House | 2025-09-23 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-08-04 | purchase | $1k – $15k |
| Robert Aderholt R-AL · House | 2025-07-28 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-24 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-17 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded GSK, with filing lags →Which hedge funds own GSK?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 2.65M | $139.06M | NEW |
| D.E. Shaw David Shaw | 1.02M | $53.44M | NEW |
| Bridgewater Associates Ray Dalio | 504K | $26.43M | -28% |
| Citadel Ken Griffin | 152K | $7.95M | NEW |
| Blackstone | 33K | $1.74M | -61% |
| Marshall Wace | 23K | $1.21M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are GSK's key statistics?
Key statistics as of Oct 31, 2026
How does GSK's valuation compare with the Healthcare sector?
| Metric | GSK | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 16.7 | 28.8 | 111 |
| Net margin | 12.97% | 3.66% | 168 |
| Return on equity | 24.64% | 3.80% | 191 |
| Dividend yield (payers) | 3.92% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 8, 2026). P/E excludes loss-making companies.
GSK price chart
Powered by TradingViewWhat does GSK plc do?
GSK plc Sponsored ADR represents shares in GSK plc, a global healthcare company headquartered in Middlesex, United Kingdom, and founded in 1715. The company focuses on the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through Commercial Operations and Research and Development segments, with Commercial Operations encompassing specialty medicines, vaccines, and general medicines. GSK plc maintains a strong presence in the pharmaceutical industry, particularly in therapeutic areas such as respiratory conditions, antivirals, and vaccines, while expanding in oncology and immunology. The company leverages joint ventures to enhance scale in markets like HIV treatments. As one of the largest firms by total sales in its sector, GSK plc plays a significant role in addressing global health needs through innovative therapies and preventive solutions, serving diverse markets worldwide.